Explore

Rapid Read Rapid Read
AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

An AI-generated drug candidate, rentosertib, developed by Insilico Medicine, has demonstrated potential in slowing aging and treating a chronic lung disease. The drug's molecular structure was created with the assistance of artificial intelligence. Clinical trial results, published in Nature Biotechnology, indicate that rentosertib successfully reduced biological markers associated with aging. While these findings are promising, the drug is still several years away from potential regulatory approval. It is important to note that the anti-aging effects of rentosertib have not yet been tested in healthy patients, with current research focusing on its impact on biological markers rather than direct anti-aging outcomes in a broader population. The development highlights the growing role of AI in drug discovery and its potential to accelerate the identification and creation of novel therapeutic compounds for complex conditions.
Rapid Read Rapid Read
Windward Bio Announces Positive Phase 2 Results for Asthma Treatment SKB378/WIN378, Initiates Phase 3 Study

Windward Bio Announces Positive Phase 2 Results for Asthma Treatment SKB378/WIN378, Initiates Phase 3 Study

Windward Bio, in partnership with Kelun-Biotech, has announced positive interim results from the Phase 2 portion of its POLARIS-1 clinical trial for SKB378/WIN378, a novel treatment for uncontrolled moderate-to-severe asthma. The study, which evaluated twice-yearly dosing, demonstrated significant and sustained improvements in lung function, measured by FEV1 (forced expiratory volume in one second), with increases of up to 174 mL (placebo-adjusted mean increase up to 256 mL). Additionally, the treatment led to dose-dependent reductions in FeNO (fractional exhaled nitric oxide) of up to 24 ppb and a decrease in mean blood eosinophil count (EOS) of up to 200 cells/µL. These effects were observed as early as Week 2 and were sustained through Week 24 after a single dose. SKB378/WIN378 was well-tolerated, with no treatment-related serious adverse events, withdrawals, or discontinuations. Following these promising results, Windward Bio has initiated the first Phase 3 study for SKB378/WIN378, with a second Phase ...
Trendline Trendline
Evommune's EVO756 Fails to Meet Primary Endpoint in Atopic Dermatitis Trial, Company Shifts Focus

Evommune's EVO756 Fails to Meet Primary Endpoint in Atopic Dermatitis Trial, Company Shifts Focus

Evommune's EVO756 Fails to Meet Primary Endpoint in Atopic Dermatitis Trial, Company Shifts Focus
Trendline Trendline
Novartis' Cholesterol-Lowering Medicine Pelacarsen Fails Phase 3 Trial, Clouding Lp(a) as a Therapeutic Target

Novartis' Cholesterol-Lowering Medicine Pelacarsen Fails Phase 3 Trial, Clouding Lp(a) as a Therapeutic Target

Novartis' Cholesterol-Lowering Medicine Pelacarsen Fails Phase 3 Trial, Clouding Lp(a) as a Therapeutic Target
Rapid Read Rapid Read
Amprion Expands Parkinson's Disease Test to Europe Through Licensing Deal with MLM Medical Labs

Amprion Expands Parkinson's Disease Test to Europe Through Licensing Deal with MLM Medical Labs

Amprion, a diagnostics company based in San Diego, has announced a strategic licensing collaboration with MLM Medical Labs, a central and specialty laboratory group with operations in Germany, the U.S., and South Africa. This agreement will enable MLM Medical Labs to validate and run Amprion's proprietary seed amplification assay (SAA) methodology in-house at its German laboratory. The test, known as SAAmplify-αSYN, detects misfolded α-synuclein protein aggregates, which are indicative of conditions like Parkinson's disease, Lewy body dementia, and multiple system atrophy. This expansion aims to make the test accessible to biopharma sponsors conducting clinical trials across Europe, eliminating the need to ship samples across the Atlantic. The SAAmplify-αSYN test received Breakthrough Device Designation from the FDA in 2019 for aiding Parkinson's diagnosis and has been commercially available in the U.S. since 2021.
Rapid Read Rapid Read
Insilico Medicine's AI-Designed Drug, Rentosertib, Shows Potential for Biological Age Reversal in Clinical Trial

Insilico Medicine's AI-Designed Drug, Rentosertib, Shows Potential for Biological Age Reversal in Clinical Trial

Insilico Medicine's AI-generated drug, rentosertib, an inhibitor of TNIK (TRAF2- and NCK-interacting kinase), has shown promising results in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF). The study, published in Nature Biotechnology, analyzed 2,841 proteins in longitudinal serum samples from 42 participants. Six independently developed proteomic aging clocks consistently indicated a reduction in biological age among participants treated with rentosertib. This finding is significant because Insilico Medicine's AI platform identified TNIK as a target relevant to both fibrosis and six recognized hallmarks of aging, integrating aging biology into the drug's development from its inception. While the study is small and short, the consistent signal across multiple aging clocks suggests a potential dual-purpose benefit for the drug, addressing both disease treatment and aging modulation. The most consistent age reduction was observed at week four with the 30 mg twice-daily regimen.
Rapid Read Rapid Read
Alzheon Publishes Peer-Reviewed Data on Oral Valiltramiprosate for Early Alzheimer's Disease

Alzheon Publishes Peer-Reviewed Data on Oral Valiltramiprosate for Early Alzheimer's Disease

Alzheon, Inc., a clinical-stage biopharmaceutical company, has announced the peer-reviewed publication of data from its Phase 3 APOLLOE4 trial and a four-year Phase 2 study in the journal *Drugs*. The publication details the effects of oral valiltramiprosate (ALZ-801) on plasma biomarkers in patients with early Alzheimer's disease (AD), particularly those who are APOE4 carriers. The studies demonstrated that valiltramiprosate achieved early and sustained reductions in key blood-based biomarkers, including plasma p-tau217 and the p-tau217/Aβ42 ratio. These reductions correlated with better cognitive, functional, and brain atrophy outcomes. According to Martin Tolar, Founder, President, and CEO of Alzheon, valiltramiprosate has shown potential to meaningfully change Alzheimer's therapy by targeting the amyloid cascade and inhibiting the formation of neurotoxic soluble amyloid oligomers. The drug maintained a favorable safety profile, with no increase in ARIA-E (amyloid-related imaging abnormalities with edem...
Rapid Read Rapid Read
Atherosclerosis May Be Classified as an Autoimmune Disease, New Research Suggests

Atherosclerosis May Be Classified as an Autoimmune Disease, New Research Suggests

New research from an international consortium, led by Professor Andreas Habenicht at LMU University Hospital and Professor Changjun Yin at Sun-Yat-Sen University in Guangzhou, China, suggests that atherosclerosis meets key criteria for an autoimmune disease. The study, published in Nature Cardiovascular Research, identifies high-affinity autoreactive antibodies that accelerate atherosclerosis when transferred into mice. One of these autoantibodies targets histone 2B. Further experiments showed that vaccinating mice with histone 2B increased the severity of atherosclerosis. These experimental findings in mice were supported by a clinical trial involving 495 patients from Guangzhou. Autoimmune diseases are characterized by the immune system attacking the body through pathogenic B cells or T cells, leading to organ damage, as seen in conditions like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. This new evidence proposes a similar mechanism for atherosclerosis, a condition previously not form...
Trendline Trendline
Novo Nordisk Halts Two Late-Stage Trials for Heart Drug Ziltivekimab

Novo Nordisk Halts Two Late-Stage Trials for Heart Drug Ziltivekimab

Novo Nordisk Halts Two Late-Stage Trials for Heart Drug Ziltivekimab
Trendline Trendline
Novo Nordisk Halts Two More Heart Disease Studies, Raising Doubts on IL-6 as a Therapeutic Target

Novo Nordisk Halts Two More Heart Disease Studies, Raising Doubts on IL-6 as a Therapeutic Target

Novo Nordisk Halts Two More Heart Disease Studies, Raising Doubts on IL-6 as a Therapeutic Target
Trendline Trendline
UCL Introduces Master's Program in Biotech and Pharmaceutical Management to Address Industry Demands

UCL Introduces Master's Program in Biotech and Pharmaceutical Management to Address Industry Demands

UCL Introduces Master's Program in Biotech and Pharmaceutical Management to Address Industry Demands
Rapid Read Rapid Read
Single IV Treatment Retrains Immune Cells to Combat Autoimmune Diseases in Early Trial

Single IV Treatment Retrains Immune Cells to Combat Autoimmune Diseases in Early Trial

Researchers have developed a novel, single intravenous (IV) treatment, JY231, that retrains a patient's immune cells to fight severe neurological and muscle autoimmune diseases. This new approach aims to simplify CAR T-cell therapy, which traditionally involves extracting, genetically modifying, and reinfusing a patient's T cells in a complex and time-consuming laboratory process. JY231 utilizes a harmless engineered lentiviral vector to deliver genetic instructions directly into the body, reprogramming the patient's own T cells to target CD19, a protein found on B cells responsible for autoimmune attacks. In an early clinical trial, 16 patients with hard-to-treat conditions such as progressive multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), generalized myasthenia gravis (gMG), and idiopathic inflammatory myopathies (IIM) received a single infusion. The treatment successfully generated CAR-T cells internally, leading to a rapid, temporary depletion of B cel...